AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015 - Abstracts presented further evaluate the safety, efficacy of HUMIRA® (adalimumab) in moderate to severe Crohn's disease, pediatric Crohn's disease and ulcerative colitis- Data examining indirect costs and family burden associated with pediatric Crohn's disease featured in oral presentation- Research presented further assesses the safety, efficacy of VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) with or without ribavirin in genotype 1 chronic hepatitis C virus (HCV) infection

NORTH CHICAGO, Ill., May 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that 18 abstracts in its gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW) 2015, May 16 – 19, in Washington, D.C. The abstracts feature results from studies further evaluating the safety and efficacy of HUMIRA® (adalimumab) and VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets). "AbbVie remains committed to making a meaningful difference in the lives of patients with serious gastroenterologic and hepatic diseases," said Scott Brun, M.D., vice president, pharmaceutical development, AbbVie. "The depth and breadth of...